Research programme: bispecific NK cell engaging antibodies - Innate Pharma/SanofiAlternative Names: Bispecific NK cell engagers - Innate Pharma/Sanofi
Latest Information Update: 14 Jan 2016
At a glance
- Originator Innate Pharma
- Developer Innate Pharma; Sanofi
- Class Antineoplastics; Bispecific antibodies
- Mechanism of Action Immunostimulants; Natural cytotoxicity triggering receptor 1 agonists; Natural killer cell stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Research Cancer